Ancient lactoferrin peptides outperformed some modern human versions against resistant bacteria
Scientists at the University of Oregon have reconstructed antimicrobial peptides from mammals that lived as far back as 160 million years ago, and some of those revived molecules hit drug-resistant bacteria harder than their modern human counterparts. The work reaches into the deep evolutionary record of lactoferrin, an immune protein found in body fluids such as breast milk, tears, saliva, mucus, and other secretions that line the front door of the body’s defenses.
The practical appeal is obvious. Antibiotic resistance keeps eroding the value of standard therapies, and the search for alternatives has pushed researchers toward molecules the body already knows how to use. Lactoferrin does two jobs at once: it binds iron so microbes cannot easily access it, and it carries a peptide sequence that can directly damage bacterial membranes. Once those membranes are perforated, bacterial cells can leak contents, lose integrity, and die.
A single amino-acid change was enough to shift the activity of one of these peptides in a major way.
Reconstructing a defense system from extinct ancestors
The project traced lactoferrin’s evolutionary history back to the earliest placental mammals, the broad group that includes humans and nearly all living mammals. Using ancestral sequence reconstruction, the investigators compared lactoferrin gene sequences from modern species such as humans and cows, mapped their evolutionary relationships, and estimated the most likely genetic sequences carried by ancient common ancestors. From those inferred genes, cells produced reconstructed proteins that mirrored versions no longer present in living mammals.
That method turns evolution into a kind of natural laboratory. Instead of designing a peptide from scratch, the team followed a molecular trail left by millions of years of selection, mutation, and retention. In the lab, the resurrected peptides were tested against several pathogens associated with human disease, including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Streptococcus.
The oldest reconstructed peptides could disrupt bacterial membranes, but the bacteria apparently repaired the injury and survived exposure. More recent ancestral versions, dating back only a few million years, became progressively stronger. In some instances, they outperformed the corresponding modern human peptides.
Small molecular shifts produced large changes in killing power
That progression is clinically interesting because it suggests the antimicrobial function evolved gradually rather than appearing fully formed. A small structural adjustment in the peptide chain was enough to alter potency substantially, and the researchers linked much of the increased activity to a single mutation in the amino-acid sequence. For a molecule built to interact with bacterial surfaces, even a subtle change in charge, shape, or membrane affinity can alter how efficiently it inserts into or destabilizes the target.
Membrane-active agents tend to work by exploiting features bacteria cannot easily hide: their surface chemistry, lipid composition, and dependence on intact membranes. If an ancestral peptide can bind more tightly or disrupt membranes with greater force, the bacterium faces a more immediate threat than it does with an iron-sequestration strategy alone. That dual pressure may explain why some of the revived molecules looked more potent than modern human versions in the assays.
Why the ancient peptides matter even if they are not near-term drugs
These peptides are not ready to become medicines on their own. They are structurally less stable than conventional antibiotics and are rapidly broken down inside the body, which limits their immediate therapeutic value. Even so, they offer a blueprint. By comparing ancient and modern versions, researchers can see which changes improved antimicrobial activity and which structural features may have made the molecules vulnerable to degradation.
That information matters because resistance is not unique to antibiotics; bacteria can adapt to antimicrobial peptides too. Understanding how pathogens respond to these molecules could help researchers design combination strategies or modified peptides that preserve activity while making resistance harder to develop. The historical record may therefore point toward new scaffolds for drug design, especially in settings where current antibiotics are losing reliability.
The study also puts a new light on a familiar immune protein. Lactoferrin is present in many tissues and secretions, yet its antimicrobial peptide component appears to have sharpened over evolutionary time. The reconstructed sequence history suggests the immune system did not settle on one optimal solution early on. It kept experimenting, and those experiments left behind molecular variants with measurable differences in bacterial killing.
Evolution as a source of therapeutic design clues
The broader message is not that ancient proteins should be taken directly from the fossil record and administered to patients. The message is that evolution has already tested countless molecular configurations under biological pressure, and some of those configurations may offer better starting points than modern human peptides alone. If one mutation can move antimicrobial activity so dramatically, then rational redesign becomes less speculative and more experimentally grounded.
For clinicians, the bedside relevance remains indirect but real: the more pathways researchers can identify for attacking bacteria, the better the odds of staying ahead of organisms that evolve resistance faster than new drugs can be built. For laboratory scientists, the resurrected peptides provide a set of comparison points that can be mined for sequence features tied to potency, stability, and resistance avoidance.
The work was funded by the National Institutes of Health and published in PLOS Biology on Aug. 25. Its main limitation is also its main caution: the most powerful ancient peptides were still laboratory constructs, not clinically usable drugs, and their instability in the body remains a major obstacle. The next questions are chemical and pharmacologic rather than historical—how to preserve the useful features of these peptides while making them durable enough for therapeutic use and less vulnerable to bacterial escape.